Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/25/2025

Janusmed sex and gender

Janusmed sex and gender – Olodaterol

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Olodaterol testing environment

Olodaterol

Class : A

Show all info

Print

Contact us

  1. Nationella riktlinjer för vård vid astma och kroniskt obstruktiv lungsjukdom (KOL). Socialstyrelsen. [updated 2018-01-29, cited 2020-09-14].

  2. Chronic obstructive pulmonary disease: olodaterol - Evidence summary [ESNM54]. National Institute for Health and Care Excellence [www]. [updated 2015-02-03, cited 2020-08-03].

  3. Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(10):CD008989.

  4. Spiolto Respimat (olodaterol/tiotropium). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-03-31, cited 2020-08-05]

  5. Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Adv Ther. 2015;32(6):523-536.

  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Nationella riktlinjer för vård vid astma och kroniskt obstruktiv lungsjukdom (KOL). Socialstyrelsen. [updated 2018-01-29, cited 2020-09-14].
  2. Chronic obstructive pulmonary disease: olodaterol - Evidence summary [ESNM54]. National Institute for Health and Care Excellence [www]. [updated 2015-02-03, cited 2020-08-03].
  3. Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(10):CD008989.
  4. Spiolto Respimat (olodaterol/tiotropium). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-03-31, cited 2020-08-05]
  5. Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Adv Ther. 2015;32(6):523-536.
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]